CME Information

A free on-line multimedia educational activity.

TITLE: LESSONS LEARNED FROM CHALLENGING MS CASES

RELEASE DATE: December 9, 2013
EXPIRATION DATE: December 8, 2014
ESTIMATED TIME TO COMPLETE THIS ACTIVITY: 1.5 hours

MEDIA: Interactive video presentation

INTENDED AUDIENCE

This activity is an on-line program developed for physician assistants, nurse practitioners, nurses, and physicians who care for ms patients.

STATEMENT OF NEED

Most health care professionals know that early treatment can slow the course of MS, but a large number are not clear about which agents best achieve this goal, and many cannot recall which risks are associated with which of the agents. This negatively impacts their willingness to prescribe disease-modifying agents, and their ability to select the optimal agent for a particular patient, which ultimately results in worse long-term outcomes.

Research has increased our knowledge of the efficacy and safety of disease-modifying agents for MS, both established agents and new ones. Many health care professionals lack knowledge sufficient to weigh the relative efficacy, risks, and mechanisms of action of these agents, and they express interest in learning more about them so that they can manage and counsel patients appropriately.

LEARNING OBJECTIVES

After completing this activity, participants should be able to:

  • Compare the mechanisms of action of various disease-modifying agents for MS and how these relate to their potential side effects
  • Evaluate disease progression and therapeutic effects using diagnostic tools such as MRI
  • Describe the long-term benefits and risks of available disease-modifying agents
  • Suggest appropriate therapy for pregnant patients with MS

FACULTY

Patricia M. Kennedy, RN, CNP, MSCN
Nurse Educator, Can Do Multiple Sclerosis, Edwards, CO

Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor of Neurology
University of Pennsylvania, Philadelphia, PA

ACCREDITATION AND CERTIFICATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Project House, Inc.  The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category I credit for completing this program.

Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.

This program is accredited for 1.5 contact hour(s) which includes .25 hour of pharmacology. Program ID #5058.AANP logo

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.5 contact hours may be earned for successful completion of this activity.

There is no charge for this activity.

Statements of Credit will be available on line following activity participation, upon completion of the on-line posttest and evaluation form available at: https://achslt.community360.net/Activity2/2073802/Activity.aspx.

DISCLOSURES

It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming.  All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:

Patricia Kennedy, RN, CNP, MSCN
Serves on a speakers' bureau and has honorarium agreements with Acorda Therapeutics, Inc.; Biogen Idec; EMD Serono; Novartis; Teva Neuroscience, Genzyme, and Questcor. Discussion of Off-Label, Investigational, or Experimental Drug Use: None.

Clyde E. Markowitz, MD
Serves on an advisory board for BioMS and Eli Lilly. He is a consultant for Bayer, Biogen-Idec, Eli Lilly, EMD Serono, and Teva Pharmaceuticals and serves on a speakers’ bureau for Bayer, Biogen-Idec, Pfizer, and Teva Pharmaceuticals.

ADDITONAL CONTENT PLANNERS

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center policy, the following disclosures have been made:

Charles Willis, Director of Continuing Education, consults for Pfizer, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have nothing to disclose.

Project House staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

DISCUSSION OF UNLABELED USES

This program mentions several unproven drugs for the management of progressive multifocal leukoencephalopathy (PML).

SYSTEM REQUIREMENTS

To participate, you will need access to a computer (either MAC or PC) with a Firefox (version 3.6 or greater) web brower or an Internet Explorer (version 8.0 or greater) web browser as well as Adobe Flash player and sound, connected to the Internet (high speed connection preferred).

CONTACT INFORMATION

For help or questions about this internet activity please contact Stephanie Phillips: Monday – Friday, 8 AM – 5 PM, Eastern Time.

Stephanie G. Phillips, PhD
sphillips@projhouse.com
Project House, Inc.
148 Majestic Rd.
Mountaindale, NY 12763
Phone: 845-436-9857

ANNENBERG CENTER FOR HEALTH SCIENCES PRIVACY POLICY

Annenberg Center for Health Sciences respects your privacy. We do not share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.5starmeded.org/shared/privacy.html

ADDITIONAL INFORMATION

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center, Project House, Inc., or their agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Lessons Learned From Challenging MS Cases is made possible by an independent educational grant from Teva Neuroscience.

This enduring material consists of an online learning activity with 2 cases on video. Successful completion is achieved by viewing the materials, reflecting on its implications in your practice, and successfully completing the assessment component. The posttest may be taken until you pass it with a passing score of 75%. To complete this activity, you must review the entire video.

The estimated time to complete the activity is 1.5 hours.

This activity was originally released on December 9, 2013 and is eligible for credit through December 8, 2014.

Copyright © 2013  Project House   ACHS 5058

 

sponsored by Annenberg and Project House
sponsored by Annenberg and Project House